Arcera CEO Isabel Afonso on anchoring life sciences in the UAE
After Make it in the Emirates, Arcera’s Isabel Afonso lays out the trends, partnerships and resilience strategy shaping the company’s next phase
24 May, 2026
TT
16
Fresh from Make it in the Emirates, the UAE’s flagship industrial showcase, Arcera Life Sciences arrived with a clear message: that pharmaceuticals are no longer peripheral to the country’s manufacturing drive, but a strategic pillar of it. The Abu Dhabi-anchored company used the event to spotlight local drug manufacturing, clinical development, genomics and a new partnership with the Emirates Drug Establishment.
In the days after, we spoke to CEO Isabel Afonso about what Arcera set out to demonstrate and where she sees the sector heading. Operating across more than 60 markets, the company is positioning itself at the intersection of the forces she believes will define life sciences’ next phase: healthcare resilience, the rise of data and genomics, and the challenge of getting innovative medicines to the patients who need them.
What did Arcera showcase at Make it in the Emirates?
Make it in the Emirates was a strong demonstration of how the UAE’s industrial ambitions are being translated into real, practical capabilities, and our participation reflected the strategic role life sciences plays in that national agenda. We illustrated how innovation, strategic partnerships and advanced pharmaceutical manufacturing strengthen healthcare resilience while contributing meaningfully to the country’s long-term industrial and economic priorities.
Arcera today operates as an integrated life sciences platform, spanning access and commercialisation of medicines, business development and scientific capability across more than 60 markets, including 13 in the Middle East. What we were advancing at the event addressed the fundamental building blocks of a strong, locally anchored sector — from ecosystem collaborations and clinical development infrastructure to the use of genomics data, Emirati talent development and scalable local manufacturing.
Taken together, these efforts reflect our ambition to help unlock the full potential of the UAE life sciences sector: strengthening resilience, enabling scale, and creating long-term value for patients and the economy.
What trends do you expect to shape your sector over the coming months?
The next phase of life sciences will be defined by the convergence of science, data, technology and systems thinking, and that shift is already accelerating.
The first major trend is healthcare resilience. Across the GCC, governments are reinforcing it with clear policy direction and tangible investment, and Arcera is actively contributing. Nearly half of our products available in the UAE are already manufactured locally, and our partnership with the Emirates Drug Establishment, announced at Make it in the Emirates, strengthens national talent development, manufacturing capacity and supply security — all of which directly benefit the healthcare system.
The second is the growing role of data and genomics in how medicines are developed and deployed. Precision medicine is moving rapidly from aspiration to practice. The availability of population-scale genomic data, combined with increasingly capable AI tools, is reshaping drug discovery and clinical development. We are exploring opportunities that position us within this intersection, and I expect it to be one of the most defining areas of advancement for the sector in the coming years.
The third is access. Chronic and complex conditions, from neurodegenerative diseases to cardiometabolic disorders and antimicrobial resistance, are growing faster than the global response. Innovation only creates value when it reaches patients, and translating scientific progress into real-world access at scale is central to our mission. It’s where our geographic reach and partnerships allow us to make a meaningful difference.
What is the anticipated growth of the sector?
The life sciences and pharmaceutical sector across the UAE and the wider GCC is expected to remain on a strong upward trajectory, underpinned by sustained government investment, industrial policy and rising healthcare demand.
According to IMARC Group, the GCC pharmaceuticals market was valued at $23.7bn in 2024 and is projected to reach $48.98bn by 2033, growing at a CAGR of 7.6 per cent. Saudi Arabia and the UAE continue to show particular momentum as both accelerate localisation, advanced manufacturing and healthcare innovation.
Importantly, growth is increasingly being measured not only in revenues but in outcomes: how many patients are reached, how many innovative medicines are approved, how resilient supply chains become, and how local talent and manufacturing capabilities are developed. That shift aligns directly with our strengths. With an integrated platform spanning access, commercialisation, business development and manufacturing, we are well-positioned to contribute as the sector evolves.
What are your plans for the next three to five years?
The coming years are about building on a strong foundation and scaling with purpose. Arcera was established with a clear mandate: to build a globally competitive life sciences company anchored in Abu Dhabi, contributing directly to the UAE’s healthcare ambitions while creating global impact. Over the past few years, we have integrated five businesses, built our core platform and established the partnerships that position us for the next phase. Now we are accelerating, around three priorities.
The first is innovation. Our collaboration with Fosun Pharma creates a long-term pipeline, technology development and a deeper focus in neuroscience, positioning Abu Dhabi as a bridge between Asian pharma innovation and global markets. We are also exploring opportunities at the intersection of genomics, clinical development and manufacturing, which will help shape new models of drug development for the region. These are structural partnerships designed to compound value over time.
The second is access. With more than 2,200 products and operations across four continents, scale is one of our strongest strategic elements. Over the next five years, we will keep expanding our pipeline and in-market portfolio, deepening regulatory capabilities and extending our geographic footprint to ensure therapies reach patients where they are needed most.
The third is strengthening local manufacturing and supply capability. More than 40 per cent of our UAE portfolio is already manufactured locally, and we intend to grow that. Our partnership with the Emirates Drug Establishment is central to building manufacturing capacity, developing strategic portfolios and advancing Emiratisation across our workforce.
What measures have you taken to stay resilient in the current environment?
Many of the measures that safeguard Arcera today were put in place well before current pressures emerged. The establishment of Arcera itself — bringing five businesses together under a single platform — was a deliberate resilience decision. From day one, the platform combined complementary capabilities, diverse therapeutic exposure and a geographically distributed operational base, which allows us to respond effectively when individual markets or supply routes face disruption.
We have also been disciplined in managing our portfolio, which spans multiple therapeutic areas, and so reduces dependency on any single category or supply source. Financially, the backing of one of Abu Dhabi’s leading sovereign investment institutions gives us the room to scale. And the partnerships we are building today are designed to extend that resilience over the long term.
























